Andexanet Alfa Vs. Four-Factor PCC: Is Andexanet Alfa Worth The Hype?
Background: Oral factor Xa inhibitors (FXi) have been associated with major and fatal bleeding events, including intracranial hemorrhage (ICH). In randomized controlled trials, both rivaroxaban and apixaban are associated with ICH at rates that range from 0.1 to 4% (Agnelli ...
